Pulike Biological Engineering Inc Class A 603566
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 23.56
- Day Range
- CNY 22.67–23.93
- 52-Week Range
- CNY 12.89–25.49
- Bid/Ask
- CNY 23.26 / CNY 23.28
- Market Cap
- CNY 8.06 Bil
- Volume/Avg
- 6.0 Mil / 3.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 66.34
- Price/Sales
- 6.89
- Dividend Yield (Trailing)
- 2.76%
- Dividend Yield (Forward)
- 2.76%
- Total Yield
- 2.76%
Company Profile
Pulike Biological Engineering Inc is engaged in the research and development and production and operation of veterinary drugs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,718
- Website
- http://www.pulike.com.cn
Comparables
Valuation
Metric
|
603566
|
300149
|
000403
|
---|---|---|---|
Price/Earnings (Normalized) | 66.34 | — | 30.60 |
Price/Book Value | 2.95 | 1.77 | 2.60 |
Price/Sales | 6.89 | 2.30 | 7.81 |
Price/Cash Flow | 33.24 | 12.91 | 37.57 |
Price/Earnings
603566
300149
000403
Financial Strength
Metric
|
603566
|
300149
|
000403
|
---|---|---|---|
Quick Ratio | 2.52 | 1.54 | 2.66 |
Current Ratio | 3.00 | 1.76 | 4.01 |
Interest Coverage | — | −30.81 | 88.68 |
Quick Ratio
603566
300149
000403
Profitability
Metric
|
603566
|
300149
|
000403
|
---|---|---|---|
Return on Assets (Normalized) | 3.63% | −29.89% | 7.64% |
Return on Equity (Normalized) | 4.33% | −45.72% | 8.84% |
Return on Invested Capital (Normalized) | 4.16% | −33.66% | 7.59% |
Return on Assets
603566
300149
000403
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Cztkghtzw | Pbd | $598.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Phkjjrtml | Knzkzh | $115.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hxwqbgfx | Ygjdjk | $109.5 Bil | |
MRNA
| Moderna Inc | Yggtjgxjj | Gxc | $54.0 Bil | |
BNTX
| BioNTech SE ADR | Xgbjdgjmf | Wckc | $24.7 Bil | |
ARGX
| argenx SE ADR | Hpwzzklzc | Pbkdz | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Btfndzjwm | Hxzqdv | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Njwkffr | Gjfxtmk | $14.5 Bil | |
INCY
| Incyte Corp | Xdncqbc | Hwwcft | $12.9 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rwclywpmv | Xvztwjb | $12.3 Bil |